logo
Select company
Select metric
Ticker Information

Ticker

SGMO

Company Name

SANGAMO THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

SANGAMO THERAPEUTICS INC - Free Cash Flow to Operating Cash Flow Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

SGMO - FCF/OCF Historical data
DateFree Cash FlowFree Cash Flow to Operating Cash FlowNet Cash Flow - Operations
6/30/2025$ -36.19M0%$ -35.9M
3/31/2025$ -44.89M0%$ -44.63M
12/31/2024$ -67.41M0%$ -67.14M
9/30/2024$ -117.11M0%$ -114.33M
6/30/2024$ -178.79M0%$ -173.38M
3/31/2024$ -218.16M0%$ -207.21M
12/31/2023$ -246M0%$ -224.84M
9/30/2023$ -257.31M0%$ -231.35M
6/30/2023$ -265.31M0%$ -237.68M
3/31/2023$ -258.48M0%$ -230.95M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • SANGAMO THERAPEUTICS INC's latest trailing twelve months (TTM) FCF/OCF stands at 88.6%.
  • Over the past 5 years, SANGAMO THERAPEUTICS INC's average FCF/OCF has been 88.07%.
  • The median FCF/OCF for SANGAMO THERAPEUTICS INC during this period was 88.6%
  • SANGAMO THERAPEUTICS INC reached its highest FCF/OCF over the past 5 years at 91.34%.
  • The lowest FCF/OCF recorded by SANGAMO THERAPEUTICS INC in the same timeframe 84.29%

SANGAMO THERAPEUTICS INC's FCF/OCF vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

FCF/OCF Benchmarks
CompanyFCF/OCF
ALEC : ALECTOR INC -BDTX : BLACK DIAMOND THERAPEUTICS INC 100.44%THTX : THERATECHNOLOGIES INC 99.84%AGEN : AGENUS INC -ENTA : ENANTA PHARMACEUTICALS INC -PLX : PROTALIX BIOTHERAPEUTICS INC -SPRO : SPERO THERAPEUTICS INC -CSBR : CHAMPIONS ONCOLOGY INC 94.33%TRDA : ENTRADA THERAPEUTICS INC -CELU : CELULARITY INC -

Definition of Free Cash Flow to Operating Cash Flow

[Calculation] The Free Cash Flow to Cash Flow from Operations ratio, describes how much of a company’s operating cash flow [NCFO] is free to be invested after capital expenditures [CapEx].
FCF / CF - Operations
(=) FCF/OCF
FCF/OCF for SANGAMO THERAPEUTICS INC is calculated as follows: FCF [ $ 135.87M ] / CF - Operations [ $ 153.35M ]
(=) FCF/OCF [ 88.6% ]

SGMO - Free Cash Flow to Operating Cash Flow, Last 5 years

84.29%

Minimum

Mar 31, 2021

91.34%

Maximum

Dec 31, 2020

88.07%

Average

88.6%

Median

FCF/OCF Benchmark Analysis

The chart above depicts the distribution of FCF/OCF for companies in the Total Stock Market. The average FCF/OCF of the companies is 71.45% with a standard deviation of 29.09%.
The following table provides additional summary stats:
FCF/OCF in the Market:
filtered constituents2.51K
min-23%
max171.58%
average71.45%
median80.76%
std29.09%